Novavax stock surges after the vaccine maker signs a $1.2 billion licensing deal with France’s Sanofi, guidance from Akamai ...

Moderna stock skidded Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative ...

Novavax stock skyrocketed Friday, up 120% on the news that French drug and vaccine giant Sanofi is investing $1.2 billion in ...

The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.

Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's ...

The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...

The FDA has not informed Moderna of any issues related to the vaccine’s safety, efficacy or quality that would prevent its ...

After that, the FDA approved the company’s updated COVID booster shot, making it available alongside shots from Moderna and ...

An analyst from Morgan Stanley persists with their Equal-Weight rating on Pfizer, maintaining a target price of $29.

A leading infectious diseases physician says overblown fears about the AstraZeneca Covid-19 vaccine probably caused more deaths than the vaccine’s rare ­adverse side effects.

AstraZeneca is withdrawing its COVID-19 vaccine from the market because of low demand, the drugmaker said Wednesday. The shot ...